Skip to main content

Dermatology

New IL-17 Inhibition New Molecular Constructs Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain. https://t.co/zz4NRITsRN https://t.co/FrUbmsjxxB
Dr. John Cush @RheumNow( View Tweet )
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N
Dr. John Cush @RheumNow( View Tweet )
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Dr. John Cush @RheumNow( View Tweet )

ICYMI: Axial Involvement in Psoriatic Arthritis

Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.

Read Article
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/ppuzIB4iRf
Dr. John Cush @RheumNow( View Tweet )
National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB
Dr. John Cush @RheumNow( View Tweet )
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ
Dr. John Cush @RheumNow( View Tweet )
Predicting Psoriatic Arthritis in Psoriasis: How Close Are We? Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies https://t.co/RLz1FoQxvc
Dr. John Cush @RheumNow( View Tweet )

Predicting Psoriatic Arthritis in Psoriasis: How Close Are We?

Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies highlighted progress in prediction strategies. Here's my review of three of them.

Read Article
#Enpatoran a #TLRi in Phase2 #SLE #RCT -previous data + small #cutaneous #lupus study various doses &PBO approx 25/group Interesting data - seems to ⬇️#IFN + endpoints 👀 for more to come! Safe so far #EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX
Janet Pope @Janetbirdope( View Tweet )
Sacroiliac joint involvement in #Psoriatic_arthritis 🔹️681 patients 🔹️Age 45 🔹️31% MRI-positive sacroiliitis 🔹️29% radiographic sacroiliitis 🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis POS0297 #EULAR2025 @RheumNow https://t.co/gKANc6mNZB
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF
Adela Castro @AdelaCastro222( View Tweet )
Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) & psoriasis (PsO) show reduced cortical volumetric bone mineral density (vBMD) & thinner cortex vs controls. Bone mechanics impaired: reduced stiffness & failure https://t.co/ghH2cwOYJc
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#digital #ulcers in #scleroderma🎯 Retrospective #iloprost vs #selexipag 👇 BIG advantage of oral #prostacyclin receptor #agonist vs iloprost healing faster ⬇️ulcers Selexipag used in iloprost failures; ⬇️IV access WOW! RCT needed #OP035 #EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd
Janet Pope @Janetbirdope( View Tweet )

Predictors and Outcomes in Systemic Sclerosis

EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article

Expanding the IL-17 Therapeutic Landscape

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% both). Should we redefine when PsA truly begins? @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F
Adela Castro @AdelaCastro222( View Tweet )
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM
Dr. Dinesh Khanna @sclerodermaUM( View Tweet )
Target trial emulation study data from British Dermatologists Biologics & Immunomodulators Register, compared 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). https://t.co/Lrpuhfarsb
Dr. John Cush @RheumNow( View Tweet )
Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.89 million in 2021 ( range of 29.95-31.82 million) - highest in USA 550/100,000. High in N.America, S.America, Southeast Asia, Australia. Lowestin Africa, Middle https://t.co/GxrZPY5NBc
Dr. John Cush @RheumNow( View Tweet )
Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi only ruxolitinib is FDA-approved, but Tofa & Bari show promise. Emerging therapies include simvastatin, afamelanotide, and metformin https://t.co/Rp2yYx6SyZ https://t.co/3RbDFVtJR5
Dr. John Cush @RheumNow( View Tweet )
Target trial emulation study data from British Dermatologists Biologics & Immunomodulators Register, compared 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). https://t.co/DSYNd9P5Om
Dr. John Cush @RheumNow( View Tweet )
×